19 November 2015 – Congratulations to Adapt Pharma for their recent NDA approval of NARCAN® (naloxone hydrochloride) nasal spray. PLC guided development of NARCAN, a needle-free nasal spray for the treatment of opioid drug overdose, and filed both the successful Fast Track Designation application and the NDA on behalf of Adapt. PLC looks forward to